RGS3 inhibits TGF‐β1/Smad signalling in adventitial fibroblasts

Xu, Fang; Liu, Ying; Shi, Lei; Cai, Hao; Liu, Wei; Hu, Yao; Li, Yuling; Yuan, Wendan

doi:10.1002/cbf.3280

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, APOB is positively correlated with secreted protein acidic and rich in cysteine (SPARC) [ 71 ], which expression is frequently associated with the excessive deposition of collagen [ 72 ] and in BC, SPARC could promote TGF-β-induced epithelial-mesenchymal transition (EMT), and further promote the tumor metastasis [ 73 ]. The overexpression of HIF1A and TGFB1 were observed in APOE knockout mice [ 74 , 75 ]. In addition, NOTCH1 signaling drives metastasis through TGF-β-dependent neutrophil recruitment [ 76 ] and crosstalk between NOTCH1 and HIF-1α has been implicated in metastasis development [ 77 ].…”

Section: Resultsmentioning

confidence: 99%

Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics

Zhu

Qian

Liao

et al. 2022

Cancers

View full text Add to dashboard Cite

Breast cancer (BC) is a serious threat to women’s health and metastasis is the major cause of BC-associated mortality. Various techniques are currently used to preoperatively describe the metastatic status of tumors, based on which a comprehensive treatment protocol was determined. However, accurately staging a tumor before surgery remains a challenge, which may lead to the miss of optimal treatment options. More severely, the failure to detect and remove occult micrometastases often causes tumor recurrences. There is an urgent need to develop a more precise and non-invasive strategy for the detection of the tumor metastasis in lymph nodes and distant organs. Based on the facts that tumor metastasis is closely related to the primary tumor microenvironment (TME) evolutions and that metabolomics profiling of the circulatory system can precisely reflect subtle changes within TME, we suppose whether metabolomic technology can be used to achieve non-invasive and real-time monitoring of BC metastatic status. In this study, the metastasis status of BC mouse models with different tumor-bearing times was firstly depicted to mimic clinical anatomic TNM staging system. Metabolomic profiling together with metastasis-related changes in TME among tumor-bearing mice with different metastatic status was conducted. A range of differential metabolites reflecting tumor metastatic states were screened and in vivo experiments proved that two main metastasis-driving factors in TME, TGF-β and hypoxia, were closely related to the regular changes of these metabolites. The differential metabolites level changes were also preliminarily confirmed in a limited number of clinical BC samples. Metabolite lysoPC (16:0) was found to be useful for clinical N stage diagnosis and the possible cause of its changes was analyzed by bioinformatics techniques.

show abstract

Section: Resultsmentioning

confidence: 99%

Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics

Zhu

Qian

Liao

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The overexpressed RGS3 in the tissues of patients with gastric cancer could lead to a poor prognosis, which could be negatively regulated by miR-126 (Wang et al, 2017). In addition, the abnormal expression of RGS3 might regulate the TGF-β signaling pathway by interfering with the heteromerization of Smad protein (Xu et al, 2017). Lu S et al reported that the overexpression of HOXD-AS1 in human hepatocyte tumors negatively regulated the expression level of RGS3, thereby inhibiting Dox-induced apoptosis (Lu S. et al, 2017), while overexpression of RGS3 in glioma cells promotes cell adhesion and metastasis (Tatenhorst et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

MiR-92a Family: A Novel Diagnostic Biomarker and Potential Therapeutic Target in Human Cancers

Jiang

Quan

et al. 2019

Front. Mol. Biosci.

View full text Add to dashboard Cite

Purpose: This study tried to explore whether members of miR-92a family contribute to early diagnosis and prognosis for human cancers and how they work.Methods: Integrated meta-analysis retrieved from public repositories was employed to assess the clinical roles of the miR-92a family for cancer diagnosis and prognosis. Expression level of miR-92a was detected by the TCGA database and was confirmed by non-small-cell lung cancer (NSCLC) tissues. Targets of miR-92a were predicted using starbase, and validated by dual luciferase assay. Correlation between miR-92a and the target gene was assessed by linkedOmics while expression of the target gene and its role in cancer prognosis were analyzed with UALCAN and Gepia.Results: We recognized the miR-92a family could serve as a potential diagnostic biomarker with a pooled sensitivity of 0.85 [0.81–0.88] and specificity of 0.86 [0.83–0.90]. The overall hazard ratio (HR) was 2.26 [95% CI: 1.70–3.00] for high expression groups compared to low expression groups. Expression of miR-92a was identified to be upregulated in NSCLC, especially in lung squamous cell carcinoma (LUSC). Results from starbase and dual luciferase assay indicated the regulator of G-protein signaling 3 (RGS3) was a direct target of miR-92a. Statistical negative correlation was found for the expression of miR-92a and RGS3. In addition, expression of RGS3 was downregulated in NSCLC and patients with the high expression had a poor prognosis (HR = 1.3) for LUSC patients. However, results were to the contrary for lung adenocarcinoma (HR = 0.7).Conclusion: This study revealed that miR-92a family could be ideal biomarkers for cancer diagnosis and prognosis, which might function through targeting RGS3.

show abstract

“…Based on the functional property of UBE2S, it is possible that autoAbs to this protein may affect cellular response to DNA damage by interfering with ubiquitin modification at DNA damage sites [37]. In addition, RGS3, a G-protein signaling inhibitor, has been implicated in cell proliferation and apoptosis in cancer [40]. Whether antibodies to this antigen also impact other immune functions or renal disease regulated by G-proteins remains to be elucidated [41], [42].…”

Section: Discussionmentioning

confidence: 99%

Novel Autoantibodies Related to Cell Death and DNA Repair Pathways in Systemic Lupus Erythematosus

Luo

Bao

Wang

et al. 2019

Genomics, Proteomics &Amp; Bioinformatics

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome characterized by various co-existing autoantibodies (autoAbs) in patients’ blood. However, the full spectrum of autoAbs in SLE has not been comprehensively elucidated. In this study, a commercial platform bearing 9400 antigens (ProtoArray) was used to identify autoAbs that were significantly elevated in the sera of SLE patients. By comparing the autoAb profiles of SLE patients with those of healthy controls, we identified 437 IgG and 1213 IgM autoAbs that the expression levels were significantly increased in SLE (P < 0.05). Use of the ProtoArray platform uncovered over 300 novel autoAbs targeting a broad range of nuclear, cytoplasmic, and membrane antigens. Molecular interaction network analysis revealed that the antigens targeted by the autoAbs were most significantly enriched in cell death, cell cycle, and DNA repair pathways. A group of autoAbs associated with cell apoptosis and DNA repair function, including those targeting APEX1, AURKA, POLB, AGO1, HMGB1, IFIT5, MAPKAPK3, PADI4, RGS3, SRP19, UBE2S, and VRK1, were further validated by ELISA and Western blot in a larger cohort. In addition, the levels of autoAbs against APEX1, HMGB1, VRK1, AURKA, PADI4, and SRP19 were positively correlated with the level of anti-dsDNA in SLE patients. Comprehensive autoAb screening has identified novel autoAbs, which may shed light on potential pathogenic pathways leading to lupus.

show abstract

RGS3 inhibits TGF‐β1/Smad signalling in adventitial fibroblasts

Cited by 8 publications

References 16 publications

Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics

Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics

MiR-92a Family: A Novel Diagnostic Biomarker and Potential Therapeutic Target in Human Cancers

Novel Autoantibodies Related to Cell Death and DNA Repair Pathways in Systemic Lupus Erythematosus

Contact Info

Product

Resources

About